How do epidemiological studies distinguish correlation from causation?

Why can't we just trust a correlation?

A correlation between two things—say, smoking and cancer—does not automatically mean one causes the other. The classic problem is confounding: a third factor could be causing both. For example, a 2024 study of head and neck cancer patients in India found a strong statistical association between tobacco use (smoking, chewing, or both) and cancer incidence (p < 0.005) [4]. But that correlation alone doesn't prove tobacco caused the cancer—it could be that people who use tobacco also share other risk factors. That's why epidemiologists need special tools to move from 'associated with' to 'causes.'

A 2024 commentary in dermatology puts it bluntly: 'Correlation does not imply causation is a common mantra in all clinical research' [6]. The article notes that even strong correlations, like the link between psoriasis and abnormal blood lipids, are hard to interpret because it's unclear which came first—the skin inflammation or the lipid problem [6]. This is where the Bradford Hill criteria come in: a set of nine viewpoints (including strength of association, consistency across studies, temporality, and dose-response) that help researchers judge whether a correlation is likely causal [6]. But these criteria are guidelines, not a mathematical proof.

How does Mendelian randomization (MR) help?

Mendelian randomization (MR) is one of the most powerful tools for inferring causation from observational data. It works like this: at conception, genetic variants are assigned randomly, much like treatment is assigned in a randomized controlled trial. So if a genetic variant is known to influence an exposure (like hearing loss), and that same variant is also linked to an outcome (like cognitive decline), then the exposure likely causes the outcome—because the genetic variant came first and wasn't affected by confounders [5][6]. A 2024 study used MR to show that hearing loss is a causal risk factor for mild cognitive impairment, with a risk ratio of 1.23 (meaning a 23% increased risk) [5]. Another MR study found that atopic dermatitis (eczema) causes certain skin cancers (squamous cell and basal cell carcinoma), but not melanoma [6].

MR can even answer the 'which came first?' question. A two-way MR analysis of psoriasis and lipid abnormalities showed that lipid problems cause psoriasis, not the other way around—opening the door to potential cholesterol-lowering treatments for psoriasis [6]. However, MR has a major limitation: it struggles when exposures are highly correlated with each other, like 97 different lipid metabolites. In that case, standard MR can produce biased or unreliable estimates because the genetic instruments are 'weak' for any single exposure [1][2][3].

What happens when exposures are too correlated to separate?

When you have many highly correlated exposures—like dozens of closely related blood lipids—standard MR can break down. A 2022 study demonstrated this problem: when they tried to estimate the causal effects of 97 different lipid traits on heart disease using multivariable MR, the statistical instruments were so weak (conditional F-statistic below 2.2, far below the recommended threshold of 10) that the results were unreliable [1][2][3]. The estimates were unstable, and even the direction of effect could flip (one lipid showed a protective effect in univariable analysis but a harmful effect in multivariable analysis) [1].

To solve this, researchers turned to dimensionality reduction techniques like principal component analysis (PCA) and sparse PCA. These methods combine correlated exposures into a smaller number of independent 'principal components'—essentially, they create new composite variables that capture the shared information [1][2][3]. In the lipid study, this approach improved instrument strength dramatically (all F-statistics crossed the threshold of 10) and produced more stable and interpretable results [1]. The best-performing method was sparse component analysis (SCA), which grouped lipids into biologically meaningful clusters (e.g., LDL-related traits together, HDL traits separately) and identified which clusters were causally linked to heart disease [1][2][3].

Can we combine different study types to strengthen causal claims?

Yes—and this is increasingly seen as the gold standard. A single observational study, no matter how well-designed, is rarely enough to prove causation. The strongest evidence comes from converging results across different designs: MR studies, traditional cohort studies, and experimental research. For example, a 2024 study on hearing loss and cognitive impairment used both MR (to establish a causal link genetically) and a cross-sectional survey of 363 elderly people (to confirm the association in a real-world population) [5]. The MR gave the causal direction; the survey provided practical cutoff values (e.g., a 9% increase in MCI risk for every decibel above a 20 dB hearing threshold) [5].

Looking ahead, a 2026 paper proposes an integrative framework for chemical mixtures that combines four approaches: human-relevant reference mixtures, hazard translation across populations, hybrid epidemiology (bridging experimental and population data), and counterfactual interventions (modeling what would happen if exposure were reduced) [7]. The goal is to move beyond correlation to causation—and ultimately to intervention—for complex environmental exposures [7]. This mirrors a broader trend: no single method is perfect, but when multiple independent lines of evidence point the same way, the case for causation becomes much stronger.

About These Sources

This answer is built on 7 peer-reviewed studies — published from 2022 to 2026, 4 from 2024 or later, 2 in Q1 journals — selected as the most relevant from 9 studies that passed quality screening, drawn from 46 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions